Emergent BioSolutions Inc. - 10-Q Summary (Period Ended June 30, 2008)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three and six-month periods ended June 30, 2008. Emergent BioSolutions Inc. is a biopharmaceutical company focused on biodefense and commercial vaccines. Its primary revenue source is BioThrax, the only FDA-approved anthrax vaccine, sold primarily to the U.S. Department of Defense (DoD) and the Department of Health and Human Services (HHS). The company operates two segments: Biodefense and Commercial.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2008 |
Six Months Ended June 30, 2007 |
|---|---|---|
| Total Revenues | $86,205 | $49,634 |
| Net Income (Loss) | $8,841 | $(7,650) |
| Diluted EPS | $0.30 | $(0.27) |
| Operating Cash Flow | $(687) | $(13,587) |
| Cash and Equivalents (End of Period) | $84,007 | $33,980 |
| Total Debt Outstanding | $59,300 | $N/A |
| Product Sales Margin | 80.0% | 76.3% |
Note: Product Sales Margin calculated as (Product Sales - Cost of Product Sales) / Product Sales.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 74% year-over-year to $86.2 million. Product sales rose 75% to $83.8 million, driven by an 82% increase in BioThrax doses delivered to HHS, partially offset by a 4% decrease in average sales price per dose.
- Profitability Turnaround: The company reported a net income of $8.8 million for the six months ended June 30, 2008, compared to a net loss of $7.7 million in the same period in 2007. This shift was driven by higher revenues and improved production yields.
- Operating Expenses: Research and Development (R&D) expenses remained relatively flat (down 1% to $28.7 million), while Selling, General, and Administrative (SG&A) expenses increased 14% to $27.1 million due to staff expansion and professional fees.
- Cash Position: Despite a net decrease in cash of $21.7 million due to significant capital expenditures ($12.5 million) and a $10 million note receivable issuance, the company ended the period with $84.0 million in cash, a substantial increase from the prior year's $34.0 million.
Guidance, Outlook, and Risks
- Manufacturing Expansion: The company is nearing completion of a new 50,000 sq. ft. manufacturing facility in Lansing, Michigan, with costs incurred to date of approximately $69 million. Large-scale manufacturing of BioThrax at this facility is anticipated to begin in 2009 pending FDA licensure.
- Contract Outlook: The company is not currently under a procurement contract with the DoD but expects future procurement to occur via the Strategic National Stockpile (SNS). A contract with HHS for 18.75 million doses (valued at $400 million) is active; a potential $34 million price adjustment is contingent on FDA approval of a four-year expiry date.
- Legal Contingencies: On July 9, 2008, the company filed suit against Protein Sciences Corporation (PSC) alleging fraud and breach of contract regarding a $10 million loan and asset purchase agreement. The company seeks damages of at least $13 million. PSC has counter-claimed and asserted a $1.5 million break-up fee.
- Regulatory Risks: The FDA conducted a routine inspection in March 2008 noting significant observations. The company is engaged in corrective action. Failure to resolve these could impact manufacturing licensure.
- Product Pipeline: The company is developing next-generation anthrax vaccines, botulinum vaccines, and commercial candidates (typhoid, hepatitis B). Enrollment in the Phase II hepatitis B trial was ceased due to recruitment difficulties.
Investor Verification Checklist
- DoD Contract Status: Verify the timeline and likelihood of securing a new direct procurement contract with the DoD, as current sales are heavily reliant on HHS SNS replenishment.
- Lansing Facility Licensure: Confirm the status of FDA licensure for the new Lansing facility, as delays could restrict capacity for future growth and commercial sales.
- PSC Litigation Outcome: Monitor the resolution of the lawsuit against Protein Sciences Corporation, which involves a $10 million receivable and potential damages.
- BioThrax Expiry Approval: Track the FDA decision on the four-year expiry dating application, which is tied to a potential $34 million revenue increase under the HHS contract.
- Product Liability Exposure: Review ongoing product liability litigation and the adequacy of indemnification provisions from the U.S. government and insurance coverage.